# FDA Advisory Panel

Type: Company

Source: GetYourBrief — https://getyourbrief.com/entity/fda-advisory-panel
Canonical HTML page: https://getyourbrief.com/entity/fda-advisory-panel

## Timeline

- **2026-08-05**: FDA final decision deadline — The agency must decide whether to approve the first mRNA-based influenza vaccine, with major implications for the platform’s future.
- **2026-08-05**: FDA Decision Deadline — The agency faces a deadline to approve or reject the vaccine.
- **2026-07**: FDA Advisory Panel Hearing — Marathon hearing votes 6-1 to back compounding of six peptide therapies, including BPC-157, TB-500, and MOTS-c, despite FDA scientists' concerns.
- **2026-06**: Advisory panel recommends approval — The FDA’s Vaccines and Related Biological Products Advisory Committee votes to recommend the mRNA flu shot for licensure.
- **2026-06**: Advisory Panel Recommends Approval — An FDA advisory panel votes in favor of approving the vaccine.
- **2026-02**: FDA refuses to review Moderna’s mRNA flu vaccine — FDA sends a refusal-to-file letter, stunning Moderna executives. Moderna had prior indications that a review would proceed.
- **2026-02**: FDA reverses decision after industry backlash — About a week later, FDA agrees to review the application after Moderna commits to a confirmatory post-market study, following public outcry and pressure.
- **2026-02**: FDA Issues Refuse-to-File Letter — FDA informs Moderna it will not review the mRNA flu shot application, surprising the company after prior assurances.
- **2026-02**: FDA Accepts Application After Outcry — A little over a week later, the agency reverses its decision after Moderna commits to a confirmatory study.

## Recent coverage (3 stories, network-wide)

### FDA Panel Greenlights 6 of 7 Peptide Therapies, Signaling Shift in Bioregulatory Framework
2026-08-03 18:47:47 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 3

Despite FDA scientists’ safety concerns, an advisory panel overwhelmingly backed six peptide therapies for compounding, including TB-500 and MOTS-c. The biotech sector watches closely as the FDA prepares for rulemaking, which may redefine the boundary between pharmaceutical development and pharmacy compounding.
Full story: https://getbiobrief.com/story/fdapanel-6-peptide-therapies-bioregulatory-shift

### Moderna's mRNA Flu Shot: FDA Decision by Aug 5 Could End 6-Month Regulatory Ordeal
2026-08-01 15:39:40 · Sector: bio · Sentiment: Neutral · Impact: 6/10 · Sources: 6

After a shocking FDA refusal-to-file in February and a subsequent advisory panel endorsement, Moderna's experimental mRNA influenza vaccine faces a final decision on August 5. The outcome holds deep implications for the viability of mRNA technology beyond COVID-19 and the future of Moderna's pipeline diversification.
Full story: https://getbiobrief.com/story/moderna-mrna-flu-shot-fda-decision-aug-5

### FDA's Aug. 5 decision on first mRNA flu shot could reshape $5B flu market
2026-08-01 14:59:02 · Sector: health · Sentiment: Neutral · Impact: 6/10 · Sources: 3

The FDA’s imminent decision on Moderna’s mRNA flu vaccine carries high stakes for healthcare providers and the vaccine industry. While an advisory panel backed approval, political skepticism from HHS Secretary RFK Jr. and a prior agency reversal add uncertainty. The ruling could either accelerate or stall mRNA’s expansion beyond COVID-19.
Full story: https://gethealthbrief.com/story/fda-mrna-flu-shot-health-regulation

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.